Skip to main content
Back
Watch Compare

SUTRO BIOPHARMA, INC.

Data quality: 100%
STRO
NASDAQ Manufacturing Chemicals
$25.86
▼ $0.90 (-3.36%)
Mkt Cap: 428.43 M
Price
$25.86
Mkt Cap
428.43 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 13.44% annually over 5 years — strong growth
Negative free cash flow of -177.23 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 51.74%

Growth

Revenue Growth (5Y)
13.44%
Above sector avg (1.82%)
Revenue (1Y)65.18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-76.78%
Net Margin-186.45%
Op. Margin-154.53%

Safety

Debt / Equity
N/A
Current Ratio2.53
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-2.24 | -10.43
Below sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -2.2 -1.5
P/B — 1.6
ROE % — -54.0
Net Margin % -186.5 -41.5
Rev Growth 5Y % 13.4 1.8
D/E — 0.3

Analyst Price Target

9 analysts
Buy
Current
$25.86
+16.4%
Target
$30.11
$9.00
$28.00
$55.00
Forecast
Forward P/E -10.43
Forward EPS -$2.48
Est. Revenue 24.87 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$2.48
-$4.56 – -$0.40
 24.87 M 2
FY2026 -$6.71
-$6.71 – -$6.71
 35.36 M 1

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$4.43 -$4.88 -10.2%
Q32025 -$3.55 -$5.57 -57.0%
Q22025 -$5.30 -$1.40 +73.6%
Q12025 N/A -$8.02 —

ETFs Holding This Stock

CNCR CNCR
0.76% weight
GCSSX GCSSX
0.07% weight
GCSAX GCSAX
0.07% weight
GCSCX GCSCX
0.07% weight
GCSIX GCSIX
0.07% weight
GDSTX GDSTX
0.07% weight
GCSUX GCSUX
0.07% weight
GMAPX GMAPX
0.07% weight
GDSRX GDSRX
0.07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 65.18% Revenue Growth (3Y) -18.35%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13.44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 102.48 M Net Income (TTM) -191.09 M
ROE N/A ROA -80.97%
Gross Margin N/A Operating Margin -154.53%
Net Margin -186.45% Free Cash Flow (TTM) -177.23 M
ROIC -76.78% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.53
Interest Coverage N/A Asset Turnover 0.43
Working Capital 110.22 M Tangible Book Value -87.27 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.24 Forward P/E -10.43
P/B Ratio N/A P/S Ratio 4.18
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 17.23 Fwd Earnings Yield N/A
FCF Yield -41.37%
Market Cap 428.43 M Enterprise Value 362.50 M
Per Share
EPS (Diluted TTM) -22.49 Revenue / Share 6.19
FCF / Share -10.70 OCF / Share -10.70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92.75%
SBC-Adj. FCF -196.13 M Growth Momentum 51.74

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 102.48 M 62.04 M 153.73 M 67.77 M 61.88 M
Net Income -191.09 M -227.46 M -106.79 M -119.20 M -105.54 M
EPS (Diluted) -22.49 -2.96 -1.78 -2.35 —
Gross Profit — — — — —
Operating Income -158.37 M -238.45 M -89.28 M -128.94 M -98.52 M
EBITDA — — — — —
R&D Expenses 166.42 M 252.04 M 180.43 M 137.17 M 104.40 M
SG&A Expenses — — — — —
D&A 7.32 M 7.22 M 6.82 M 5.69 M 4.84 M
Interest Expense — — 1.30 M 2.40 M 2.60 M
Income Tax -93,000.0 2.36 M 18.19 M 2.50 M 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 173.83 M 387.21 M 470.74 M 406.94 M 341.41 M
Total Liabilities 306.28 M 342.61 M 321.09 M 189.90 M 88.84 M
Shareholders' Equity -132.45 M 44.60 M 149.65 M 217.05 M 252.56 M
Total Debt — — 4.06 M 16.27 M 25.11 M
Cash & Equivalents 58.13 M 190.30 M 69.27 M 47.25 M 30.41 M
Current Assets 150.93 M 343.31 M 421.54 M 353.15 M 218.52 M
Current Liabilities 75.13 M 131.89 M 93.75 M 66.55 M 41.74 M